{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:12:01Z","timestamp":1791191521672,"version":"4.1.0"},"reference-count":86,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/nrd4102","type":"journal-article","created":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T08:31:29Z","timestamp":1380616289000},"page":"777-790","source":"Crossref","is-referenced-by-count":104,"title":["Drug discovery for autism spectrum disorder: challenges and opportunities"],"prefix":"10.1038","volume":"12","author":[{"given":"Anirvan","family":"Ghosh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubin","family":"Michalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Lindemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"BFnrd4102_CR1","first-page":"217","volume":"2","author":"L Kanner","year":"1943","unstructured":"Kanner, L. Autistic disturbances of affective contact. Nerv. Child. 2, 217\u2013250 (1943).","journal-title":"Nerv. Child."},{"key":"BFnrd4102_CR2","first-page":"1314","volume":"51","author":"H Asperger","year":"1938","unstructured":"Asperger, H. The psychically abnormal child, Wien Klin. Wochenschr. 51, 1314\u20131317 (1938).","journal-title":"Wien Klin. Wochenschr."},{"key":"BFnrd4102_CR3","unstructured":"Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders \u2014 Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill. Summ. 61, 1\u201319 (2012)."},{"key":"BFnrd4102_CR4","doi-asserted-by":"publisher","unstructured":"Politte, L. C. & McDougle, C. J. Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl). 2013 (dx. http:\/\/dx.doi.org\/10.1007\/s00213-013-3068-y ).","DOI":"10.1007\/s00213-013-3068-y"},{"key":"BFnrd4102_CR5","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1788","volume":"14","author":"D Ehninger","year":"2008","unstructured":"Ehninger, D. et al. Reversal of learning deficits in a Tsc2+\/\u2212 mouse model of tuberous sclerosis. Nature Med. 14, 843\u2013848 (2008).","journal-title":"Nature Med."},{"key":"BFnrd4102_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.neuron.2012.03.009","volume":"74","author":"A Michalon","year":"2012","unstructured":"Michalon, A. et al. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49\u201356 (2012).","journal-title":"Neuron"},{"key":"BFnrd4102_CR7","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/nature711","volume":"415","author":"RM Costa","year":"2002","unstructured":"Costa, R. M. et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 415, 526\u2013530 (2002).","journal-title":"Nature"},{"key":"BFnrd4102_CR8","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1073\/pnas.0812394106","volume":"106","author":"D Tropea","year":"2009","unstructured":"Tropea, D. et al. Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl Acad. Sci. USA 106, 2029\u20132034 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4102_CR9","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1523\/JNEUROSCI.0955-08.2008","volume":"28","author":"L Meikle","year":"2008","unstructured":"Meikle, L. et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J. Neurosci. 28, 5422\u20135432 (2008).","journal-title":"J. Neurosci."},{"key":"BFnrd4102_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/ajmg.b.31159","volume":"156B","author":"A Ronald","year":"2011","unstructured":"Ronald, A. & Hoekstra, R. A. Autism spectrum disorders and autistic traits: a decade of new twin studies. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156B, 255\u2013274 (2011).","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"BFnrd4102_CR11","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s11910-009-0029-2","volume":"9","author":"RA Kumar","year":"2009","unstructured":"Kumar, R. A. & Christian, S. L. Genetics of autism spectrum disorders. Curr. Neurol. Neurosci. Rep. 9, 188\u2013197 (2009).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrd4102_CR12","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.brainres.2010.11.078","volume":"1380","author":"C Betancur","year":"2011","unstructured":"Betancur, C. Etiological heterogeneity in autism spectrum disorders: more than 100 genetic and genomic disorders and still counting. Brain Res. 1380, 42\u201377 (2011).","journal-title":"Brain Res."},{"key":"BFnrd4102_CR13","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/978-1-61779-507-7_5","volume":"838","author":"CR Marshall","year":"2012","unstructured":"Marshall, C. R. & Scherer, S. W. Detection and characterization of copy number variation in autism spectrum disorder. Methods Mol. Biol. 838, 115\u2013135 (2012).","journal-title":"Methods Mol. Biol."},{"key":"BFnrd4102_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature11396","volume":"488","author":"A Kong","year":"2012","unstructured":"Kong, A. et al. Rate of de novo mutations and the importance of father's age to disease risk. Nature 488, 471\u2013475 (2012).","journal-title":"Nature"},{"key":"BFnrd4102_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrg3118","volume":"13","author":"G Gibson","year":"2012","unstructured":"Gibson, G. Rare and common variants: twenty arguments. Nature Rev. Genet. 13, 135\u2013145 (2012).","journal-title":"Nature Rev. Genet."},{"key":"BFnrd4102_CR16","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/nrg2918","volume":"12","author":"AL Barabasi","year":"2011","unstructured":"Barabasi, A. L., Gulbahce, N. & Loscalzo, J. Network medicine: a network-based approach to human disease. Nature Rev. Genet. 12, 56\u201368 (2011).","journal-title":"Nature Rev. Genet."},{"key":"BFnrd4102_CR17","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.conb.2012.02.015","volume":"22","author":"J Peca","year":"2012","unstructured":"Peca, J. & Feng, G. Cellular and synaptic network defects in autism. Curr. Opin. Neurobiol. 22, 866\u2013872 (2012).","journal-title":"Curr. Opin. Neurobiol."},{"key":"BFnrd4102_CR18","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/emboj.2011.182","volume":"30","author":"MR Etherton","year":"2011","unstructured":"Etherton, M. R., Tabuchi, K., Sharma, M., Ko, J. & Sudhof, T. C. An autism-associated point mutation in the neuroligin cytoplasmic tail selectively impairs AMPA receptor-mediated synaptic transmission in hippocampus. EMBO J. 30, 2908\u20132919 (2011).","journal-title":"EMBO J."},{"key":"BFnrd4102_CR19","doi-asserted-by":"publisher","first-page":"13764","DOI":"10.1073\/pnas.1111093108","volume":"108","author":"M Etherton","year":"2011","unstructured":"Etherton, M. et al. Autism-linked neuroligin-3 R451C mutation differentially alters hippocampal and cortical synaptic function. Proc. Natl Acad. Sci. USA 108, 13764\u201313769 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4102_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.cell.2008.10.017","volume":"135","author":"RJ Kelleher 3rd","year":"2008","unstructured":"Kelleher, R. J., 3rd & Bear, M. F. The autistic neuron: troubled translation? Cell 135, 401\u2013406 (2008).","journal-title":"Cell"},{"key":"BFnrd4102_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1146\/annurev-genet-110410-132512","volume":"45","author":"H van Bokhoven","year":"2011","unstructured":"van Bokhoven, H. Genetic and epigenetic networks in intellectual disabilities. Annu. Rev. Genet. 45, 81\u2013104 (2011).","journal-title":"Annu. Rev. Genet."},{"key":"BFnrd4102_CR22","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/ddrr.80","volume":"15","author":"A Schneider","year":"2009","unstructured":"Schneider, A., Hagerman, R. J. & Hessl, D. Fragile X syndrome \u2014 from genes to cognition. Dev. Disabil Res. Rev. 15, 333\u2013342 (2009).","journal-title":"Dev. Disabil Res. Rev."},{"key":"BFnrd4102_CR23","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1146\/annurev-med-061109-134644","volume":"62","author":"DD Krueger","year":"2011","unstructured":"Krueger, D. D. & Bear, M. F. Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411\u2013429 (2011).","journal-title":"Annu. Rev. Med."},{"key":"BFnrd4102_CR24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.neuron.2007.12.001","volume":"56","author":"G D\u00f6len","year":"2007","unstructured":"D\u00f6len, G. et al. Correction of fragile X syndrome in mice. Neuron 56, 955\u2013962 (2007).","journal-title":"Neuron"},{"key":"BFnrd4102_CR25","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nrn2870","volume":"11","author":"EM Hur","year":"2010","unstructured":"Hur, E. M. & Zhou, F. Q. GSK3 signalling in neural development. Nature Rev. Neurosci. 11, 539\u2013551 (2010).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrd4102_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/jmg.2008.061796","volume":"46","author":"TV Bilousova","year":"2009","unstructured":"Bilousova, T. V. et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J. Med. Genet. 46, 94\u2013102 (2009).","journal-title":"J. Med. Genet."},{"key":"BFnrd4102_CR27","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.bcp.2009.09.023","volume":"79","author":"CJ Yuskaitis","year":"2010","unstructured":"Yuskaitis, C. J. et al. Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. Biochem. Pharmacol. 79, 632\u2013646 (2010).","journal-title":"Biochem. Pharmacol."},{"key":"BFnrd4102_CR28","doi-asserted-by":"publisher","first-page":"e9706","DOI":"10.1371\/journal.pone.0009706","volume":"5","author":"MA Mines","year":"2010","unstructured":"Mines, M. A., Yuskaitis, C. J., King, M. K., Beurel, E. & Jope, R. S. GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. PLoS ONE 5, e9706 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrd4102_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1159\/000329420","volume":"33","author":"SM Paluszkiewicz","year":"2011","unstructured":"Paluszkiewicz, S. M., Martin, B. S. & Huntsman, M. M. Fragile X syndrome: the GABAergic system and circuit dysfunction. Dev. Neurosci. 33, 349\u2013364 (2011).","journal-title":"Dev. Neurosci."},{"key":"BFnrd4102_CR30","doi-asserted-by":"publisher","first-page":"152ra128","DOI":"10.1126\/scitranslmed.3004218","volume":"4","author":"C Henderson","year":"2012","unstructured":"Henderson, C. et al. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen. Sci. Transl. Med. 4, 152ra128 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd4102_CR31","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(08)61279-9","volume":"372","author":"P Curatolo","year":"2008","unstructured":"Curatolo, P., Bombardieri, R. & Jozwiak, S. Tuberous sclerosis. Lancet 372, 657\u2013668 (2008).","journal-title":"Lancet"},{"key":"BFnrd4102_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/nn1566","volume":"8","author":"SF Tavazoie","year":"2005","unstructured":"Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J. & Sabatini, B. L. Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2. Nature Neurosci. 8, 1727\u20131734 (2005).","journal-title":"Nature Neurosci."},{"key":"BFnrd4102_CR33","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1523\/JNEUROSCI.5540-06.2007","volume":"27","author":"L Meikle","year":"2007","unstructured":"Meikle, L. et al. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J. Neurosci. 27, 5546\u20135558 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrd4102_CR34","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1158\/1078-0432.CCR-11-0445","volume":"17","author":"DM Davies","year":"2011","unstructured":"Davies, D. M. et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin. Cancer Res. 17, 4071\u20134081 (2011).","journal-title":"Clin. Cancer Res."},{"key":"BFnrd4102_CR35","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler, J. J. et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N. Engl. J. Med. 358, 140\u2013151 (2008).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4102_CR36","doi-asserted-by":"publisher","first-page":"e23379","DOI":"10.1371\/journal.pone.0023379","volume":"6","author":"SL Dabora","year":"2011","unstructured":"Dabora, S. L. et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease. PLoS ONE 6, e23379 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrd4102_CR37","doi-asserted-by":"publisher","first-page":"131ra51","DOI":"10.1126\/scitranslmed.3003501","volume":"4","author":"JL Silverman","year":"2012","unstructured":"Silverman, J. L. et al. Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism. Sci. Transl. Med. 4, 131ra51 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd4102_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nature10658","volume":"480","author":"BD Auerbach","year":"2011","unstructured":"Auerbach, B. D., Osterweil, E. K. & Bear, M. F. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63\u201368 (2011).","journal-title":"Nature"},{"key":"BFnrd4102_CR39","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.tips.2012.09.004","volume":"33","author":"W Spooren","year":"2012","unstructured":"Spooren, W., Lindemann, L., Ghosh, A. & Santarelli, L. Synapse dysfunction in autism: a molecular medicine approach to drug discovery in neurodevelopmental disorders. Trends Pharm. Sci 33, 669\u2013684 (2012).","journal-title":"Trends Pharm. Sci"},{"key":"BFnrd4102_CR40","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tins.2011.04.001","volume":"34","author":"AM Mabb","year":"2012","unstructured":"Mabb, A. M., Judson, M. C., Zylka, M. J. & Philpot, B. D. Angelman syndrome: insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 34, 293\u2013303 (2012).","journal-title":"Trends Neurosci."},{"key":"BFnrd4102_CR41","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1073\/pnas.1007753108","volume":"108","author":"JE Kim","year":"2011","unstructured":"Kim, J. E. et al. Investigating synapse formation and function using human pluripotent stem cell-derived neurons. Proc. Natl Acad. Sci. USA 108, 3005\u20133010 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4102_CR42","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1126\/science.1158799","volume":"321","author":"JT Dimos","year":"2008","unstructured":"Dimos, J. T. et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321, 1218\u20131221 (2008).","journal-title":"Science"},{"key":"BFnrd4102_CR43","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.cell.2010.10.016","volume":"143","author":"MC Marchetto","year":"2010","unstructured":"Marchetto, M. C. et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527\u2013539 (2010).","journal-title":"Cell"},{"key":"BFnrd4102_CR44","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/nm.2576","volume":"17","author":"SP Pasca","year":"2011","unstructured":"Pasca, S. P. et al. Using iPSC-derived neurons to uncover cellular phenotypes associated with Timothy syndrome. Nature Med. 17, 1657\u20131662 (2011).","journal-title":"Nature Med."},{"key":"BFnrd4102_CR45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1601-183X.2007.00330.x","volume":"7","author":"HG McFarlane","year":"2008","unstructured":"McFarlane, H. G. et al. Autism-like behavioral phenotypes in BTBR T+tf\/J mice. Genes Brain Behav. 7, 152\u2013163 (2008).","journal-title":"Genes Brain Behav."},{"key":"BFnrd4102_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ntt.2013.01.004","volume":"36","author":"FI Roullet","year":"2013","unstructured":"Roullet, F. I., Lai, J. K. & Foster, J. A. In utero exposure to valproic acid and autism \u2014 a current review of clinical and animal studies. Neurotoxicol. Teratol. 36, 47\u201356 (2013).","journal-title":"Neurotoxicol. Teratol."},{"key":"BFnrd4102_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/nrn2851","volume":"11","author":"JL Silverman","year":"2010","unstructured":"Silverman, J. L., Yang, M., Lord, C. & Crawley, J. N. Behavioural phenotyping assays for mouse models of autism. Nature Rev. Neurosci. 11, 490\u2013502 (2010).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrd4102_CR48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.31887\/DCNS.2012.14.3\/jcrawley","volume":"14","author":"JN Crawley","year":"2012","unstructured":"Crawley, J. N. Translational animal models of autism and neurodevelopmental disorders. Dialogues Clin. Neurosci. 14, 293\u2013305 (2012).","journal-title":"Dialogues Clin. Neurosci."},{"key":"BFnrd4102_CR49","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1601-183X.2010.00623.x","volume":"10","author":"ML Scattoni","year":"2011","unstructured":"Scattoni, M. L., Ricceri, L. & Crawley, J. N. Unusual repertoire of vocalizations in adult BTBR T+tf\/J mice during three types of social encounters. Genes Brain Behav. 10, 44\u201356 (2011).","journal-title":"Genes Brain Behav."},{"key":"BFnrd4102_CR50","doi-asserted-by":"publisher","first-page":"11074","DOI":"10.1073\/pnas.1005620107","volume":"107","author":"DM Young","year":"2010","unstructured":"Young, D. M., Schenk, A. K., Yang, S. B., Jan, Y. N. & Jan, L. Y. Altered ultrasonic vocalizations in a tuberous sclerosis mouse model of autism. Proc. Natl Acad. Sci. USA 107, 11074\u201311079 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4102_CR51","doi-asserted-by":"publisher","first-page":"e44816","DOI":"10.1371\/journal.pone.0044816","volume":"7","author":"S Roy","year":"2012","unstructured":"Roy, S., Watkins, N. & Heck, D. Comprehensive analysis of ultrasonic vocalizations in a mouse model of fragile X syndrome reveals limited, call type specific deficits. PLoS ONE 7, e44816 (2012).","journal-title":"PLoS ONE"},{"key":"BFnrd4102_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.brainres.2011.12.041","volume":"1439","author":"SE Rotschafer","year":"2012","unstructured":"Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M. & Razak, K. A. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of fragile X syndrome. Brain Res. 1439, 7\u201314 (2012).","journal-title":"Brain Res."},{"key":"BFnrd4102_CR53","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1469-7610.2004.00266.x","volume":"45","author":"JN Constantino","year":"2004","unstructured":"Constantino, J. N. et al. The factor structure of autistic traits. J. Child Psychol. Psychiatry 45, 719\u2013726 (2004).","journal-title":"J. Child Psychol. Psychiatry"},{"key":"BFnrd4102_CR54","doi-asserted-by":"publisher","first-page":"64ra1","DOI":"10.1126\/scitranslmed.3001708","volume":"3","author":"S Jacquemont","year":"2011","unstructured":"Jacquemont, S. et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci. Transl. Med. 3, 64ra1 (2011).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd4102_CR55","doi-asserted-by":"publisher","first-page":"152ra127","DOI":"10.1126\/scitranslmed.3004214","volume":"4","author":"EM Berry-Kravis","year":"2012","unstructured":"Berry-Kravis, E. M. et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, Phase 2 trial. Sci. Transl. Med. 4, 152ra127 (2012).","journal-title":"Sci. Transl. Med."},{"key":"BFnrd4102_CR56","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/DBP.0b013e31817dc447","volume":"29","author":"E Berry-Kravis","year":"2008","unstructured":"Berry-Kravis, E. et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J. Dev. Behav. Pediatr. 29, 293\u2013302 (2008).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"BFnrd4102_CR57","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1471-2377-10-91","volume":"10","author":"C Paribello","year":"2010","unstructured":"Paribello, C. et al. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol. 10, 91 (2010).","journal-title":"BMC Neurol."},{"key":"BFnrd4102_CR58","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/DBP.0b013e318287cd17","volume":"34","author":"MJ Leigh","year":"2013","unstructured":"Leigh, M. J. et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile X syndrome. J. Dev. Behav. Pediatr. 34, 147\u2013155 (2013).","journal-title":"J. Dev. Behav. Pediatr."},{"key":"BFnrd4102_CR59","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1111\/j.1469-7610.2010.02349.x","volume":"52","author":"KA Pelphrey","year":"2011","unstructured":"Pelphrey, K. A., Shultz, S., Hudac, C. M. & Vander Wyk, B. C. Research review: Constraining heterogeneity: the social brain and its development in autism spectrum disorder. J. Child Psychol. Psychiatry 52, 631\u2013644 (2011).","journal-title":"J. Child Psychol. Psychiatry"},{"key":"BFnrd4102_CR60","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s10803-011-1176-2","volume":"41","author":"F Farzin","year":"2011","unstructured":"Farzin, F., Scaggs, F., Hervey, C., Berry-Kravis, E. & Hessl, D. Reliability of eye tracking and pupillometry measures in individuals with fragile X syndrome. J. Autism Dev. Disord. 41, 1515\u20131522 (2011).","journal-title":"J. Autism Dev. Disord."},{"key":"BFnrd4102_CR61","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.yhbeh.2012.01.016","volume":"61","author":"CF Zink","year":"2012","unstructured":"Zink, C. F. & Meyer-Lindenberg, A. Human neuroimaging of oxytocin and vasopressin in social cognition. Horm. Behav. 61, 400\u2013409 (2012).","journal-title":"Horm. Behav."},{"key":"BFnrd4102_CR62","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1073\/pnas.0910249107","volume":"107","author":"E Andari","year":"2010","unstructured":"Andari, E. et al. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc. Natl Acad. Sci. USA 107, 4389\u20134394 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrd4102_CR63","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10803-011-1370-2","volume":"42","author":"SM Sansone","year":"2012","unstructured":"Sansone, S. M. et al. Psychometric study of the aberrant behavior checklist in fragile X syndrome and implications for targeted treatment. J. Autism Dev. Disord. 42, 1377\u20131392 (2012).","journal-title":"J. Autism Dev. Disord."},{"key":"BFnrd4102_CR64","volume-title":"International Society for Autism Research","author":"J Veenstra-VanderWeele","year":"2013","unstructured":"Veenstra-VanderWeele, J. et al. Randomized, controlled, Phase 2 trial of STX209 for social function in ASD. International Society for Autism Research [online] , (2013)."},{"key":"BFnrd4102_CR65","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1176\/appi.ajp.162.6.1133","volume":"162","author":"S Chakrabarti","year":"2005","unstructured":"Chakrabarti, S. & Fombonne, E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am. J. Psychiatry 162, 1133\u20131141 (2005).","journal-title":"Am. J. Psychiatry"},{"key":"BFnrd4102_CR66","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1097\/CHI.0b013e318179964f","volume":"47","author":"E Simonoff","year":"2008","unstructured":"Simonoff, E. et al. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. J. Am. Acad. Child Adolesc. Psychiatry 47, 921\u2013929 (2008).","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"BFnrd4102_CR67","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s10803-010-0958-2","volume":"40","author":"ML Mattila","year":"2010","unstructured":"Mattila, M. L. et al. Comorbid psychiatric disorders associated with Asperger syndrome\/high-functioning autism: a community- and clinic-based study. J. Autism Dev. Disord. 40, 1080\u20131093 (2010).","journal-title":"J. Autism Dev. Disord."},{"key":"BFnrd4102_CR68","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/aur.124","volume":"3","author":"BA Boyd","year":"2010","unstructured":"Boyd, B. A. et al. Sensory features and repetitive behaviors in children with autism and developmental delays. Autism Res. 3, 78\u201387 (2010).","journal-title":"Autism Res."},{"key":"BFnrd4102_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yebeh.2005.11.001","volume":"8","author":"MG Chez","year":"2006","unstructured":"Chez, M. G. et al. Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005. Epilepsy Behav. 8, 267\u2013271 (2006).","journal-title":"Epilepsy Behav."},{"key":"BFnrd4102_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1542\/peds.2009-1878C","volume":"125","author":"T Buie","year":"2010","unstructured":"Buie, T. et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics 125 (Suppl. 1), 1\u201318 (2010).","journal-title":"Pediatrics"},{"key":"BFnrd4102_CR71","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11065-008-9073-y","volume":"18","author":"GA Stefanatos","year":"2008","unstructured":"Stefanatos, G. A. Regression in autistic spectrum disorders. Neuropsychol. Rev. 18, 305\u2013319 (2008).","journal-title":"Neuropsychol. Rev."},{"key":"BFnrd4102_CR72","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1203\/PDR.0b013e31819e7203","volume":"65","author":"E Fombonne","year":"2009","unstructured":"Fombonne, E. Epidemiology of pervasive developmental disorders. Pediatr. Res. 65, 591\u2013598 (2009).","journal-title":"Pediatr. Res."},{"key":"BFnrd4102_CR73","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/clpt.2011.321","volume":"91","author":"M Goldman","year":"2012","unstructured":"Goldman, M. The innovative medicines initiative: a European response to the innovation challenge. Clin. Pharmacol. Ther. 91, 418\u2013425 (2012).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrd4102_CR74","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1586\/erp.12.59","volume":"12","author":"H Laverty","year":"2012","unstructured":"Laverty, H., Gunn, M. & Goldman, M. Improving R&D productivity of pharmaceutical companies through public\u2013private partnership: experiences from the Innovative Medicines Initiative. Expert Rev. Pharmacoecon. Outcomes Res. 12, 545\u2013548 (2012).","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"key":"BFnrd4102_CR75","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nrd3881","volume":"11","author":"D Murphy","year":"2012","unstructured":"Murphy, D. & Spooren, W. EU-AIMS: a boost to autism research. Nature Rev. Drug Discov. 11, 815\u2013816 (2012).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd4102_CR76","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/2040-2392-3-9","volume":"3","author":"L Klei","year":"2012","unstructured":"Klei, L. et al. Common genetic variants, acting additively, are a major source of risk for autism. Mol. Autism 3, 9 (2012).","journal-title":"Mol. Autism"},{"key":"BFnrd4102_CR77","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature11011","volume":"485","author":"BM Neale","year":"2012","unstructured":"Neale, B. M. et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature 485, 242\u2013245 (2012).","journal-title":"Nature"},{"key":"BFnrd4102_CR78","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2012.11.019","volume":"151","author":"JJ Michaelson","year":"2012","unstructured":"Michaelson, J. J. et al. Whole-genome sequencing in autism identifies hot spots for de novo germline mutation. Cell 151, 1431\u20131442 (2012).","journal-title":"Cell"},{"key":"BFnrd4102_CR79","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nature08494","volume":"461","author":"TA Manolio","year":"2009","unstructured":"Manolio, T. A. et al. Finding the missing heritability of complex diseases. Nature 461, 747\u2013753 (2009).","journal-title":"Nature"},{"key":"BFnrd4102_CR80","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJMoa1200395","volume":"367","author":"S Girirajan","year":"2012","unstructured":"Girirajan, S. et al. Phenotypic heterogeneity of genomic disorders and rare copy-number variants. N. Engl. J. Med. 367, 1321\u20131331 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd4102_CR81","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2217\/epi.11.18","volume":"3","author":"M Ollikainen","year":"2011","unstructured":"Ollikainen, M. & Craig, J. M. Epigenetic discordance at imprinting control regions in twins. Epigenomics 3, 295\u2013306 (2011).","journal-title":"Epigenomics"},{"key":"BFnrd4102_CR82","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nrg2344","volume":"9","author":"MI McCarthy","year":"2008","unstructured":"McCarthy, M. I. et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nature Rev. Genet. 9, 356\u2013369 (2008).","journal-title":"Nature Rev. Genet."},{"key":"BFnrd4102_CR83","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.tins.2009.04.003","volume":"32","author":"C Betancur","year":"2009","unstructured":"Betancur, C., Sakurai, T. & Buxbaum, J. D. The emerging role of synaptic cell-adhesion pathways in the pathogenesis of autism spectrum disorders. Trends Neurosci. 32, 402\u2013412 (2009).","journal-title":"Trends Neurosci."},{"key":"BFnrd4102_CR84","doi-asserted-by":"publisher","first-page":"D808","DOI":"10.1093\/nar\/gks1094","volume":"41","author":"A Franceschini","year":"2013","unstructured":"Franceschini, A. et al. STRING v9.1: protein\u2013protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 41, D808\u2013D815 (2013).","journal-title":"Nucleic Acids Res."},{"key":"BFnrd4102_CR85","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.cell.2011.06.013","volume":"146","author":"JC Darnell","year":"2011","unstructured":"Darnell, J. C. et al. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247\u2013261 (2011).","journal-title":"Cell"},{"key":"BFnrd4102_CR86","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nmeth.2212","volume":"9","author":"R Saito","year":"2012","unstructured":"Saito, R. et al. A travel guide to Cytoscape plugins. Nature Methods 9, 1069\u20131076 (2012).","journal-title":"Nature Methods"}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd4102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd4102","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd4102.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T09:39:32Z","timestamp":1716025172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd4102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":86,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["BFnrd4102"],"URL":"https:\/\/doi.org\/10.1038\/nrd4102","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}